Reconsidering tolerability of cancer treatments: opportunities to focus on the patient
Author:
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
https://link.springer.com/content/pdf/10.1007/s00520-021-06700-0.pdf
Reference8 articles.
1. Kluetz PG, Kanapuru B, Lemery S et al (2018) Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and critical path institute workshop. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 21(6):742–747
2. Basch E, Campbell A, Hudgens S et al (2020) Broadening the definition of tolerability in cancer clinical trials to capture the patient experience. Friends of Cancer, Washington, DC
3. Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and reliability of the U.S. National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA oncology. 1(8):1051–1059
4. Basch E, Becker C, Rogak LJ et al (2021) Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials 18(1):104–114
5. Webster KA, Peipert JD, Lent LF, Bredle J, Cella D (2022) The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: guidance for use in research and clinical practice. In: Kassianos A (Ed.) Handbook of quality of life in cancer, 1st edn. Springer International Publishing, New York
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Assessing Side-Effect Bother, Burden, and Tolerability: A Qualitative Study Exploring the Content Validity of the Functional Assessment of Cancer Therapy – Item GP5;2024-08-26
2. [Special issue PRO] Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework;Journal of Biopharmaceutical Statistics;2024-02-15
3. Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial;Journal of Clinical Oncology;2024-01-20
4. Organic Nanomaterials Loaded with Cytotoxic Agents: A Therapeutic Alternative Against Cancer;Interdisciplinary Cancer Research;2024
5. Critical gaps in understanding treatment outcomes in adolescents and young adults with lymphoma: A review of current data;eJHaem;2023-08-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3